Patent classifications
G01N33/56983
MARKER COMBINATIONS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF
A method of determining an infection type in a subject is disclosed. The method comprises measuring the concentration of a first determinant selected from the group consisting of the determinants which are set forth in Table 1 and a second determinant selected from the group of the determinants which are set forth in Table 2 in a subject derived sample, wherein the concentration is indicative of the infection type.
COMPOSITE COMPRISING ANTIBODY CAPABLE OF BINDING TO INTRANUCLEAR PROTEIN OF INFLUENZA VIRUS
The present invention provides a composite comprising a novel antibody and at least one selected from the group consisting of a solid phase support and a labeled substance. The antibody consists of the amino acid sequence represented by SEQ ID NO: 08, and is capable of binding to an intranuclear protein of an influenza virus type A. The influenza virus type A is at least one selected from the group consisting of H1N1, H2N2, H3N2, and H7N9. The antibody is bound to the at least one selected from the group consisting of a solid phase support. The present invention also provides a detection device and a detection method using the composite.
RECOMBINANT CLASSICAL SWINE FEVER VIRUS
Provided are a recombinant classical swine fever virus comprising at least one substitution within the epitope of the E2 protein specifically recognized by the 6B8 monoclonal antibody, an immunogenic composition comprising said CSFV, the use of said immunogenic composition for preventing and/or treating diseases associated with CSFV in an animal, a method or a kit for differentiating animals infected with CSFV from animals vaccinated with said immunogenic composition, and an attenuated classical swine fever viruses.
COLORIMETRIC DETECTION SYSTEM FOR RAPID DETECTION OF INFECTIOUS PULMONARY DISEASES AND A FACE MASK WITH SAID COLORIMETRIC DETECTION SYSTEM
The present invention relates to a colorimetric detection system for rapid detection of lung diseases. The detection system comprises antibodies and/or aptamers coupled to a substrate for capturing a lung disease specific antigen. The colorimetric system further comprises dyed microspheres modified with the antibodies and/or aptamers for visually detecting the lung disease specific antigen. The present invention also relates to a method of producing said detection system and a mask with such a detection system.
System for detecting a target material in a sample using liquid crystals
A system for detecting a target material in a sample. The system includes a sensor, a light source, an image-capturing device, two linear-crossed polarizers including a first polarizer and a second polarizer, and a processing unit. The sensor is configured to place the sample thereon and includes a fabric impregnated with liquid crystals (LCs). The light source is configured to transmit a beam of light through a path passing from the first polarizer, the sensor, and the second polarizer. The image-capturing device is configured to capture an image of a surface of the second polarizer. The image contains a pattern formed by orientations of LCs corresponding to the sample. The processing unit is configured to detect a presence of the target material in the sample by analyzing the captured image.
COMPOSITIONS AND METHODS RELATED TO VIRAL VACCINES
Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
VIRAL SEROLOGY ACE2 COMPETITION ASSAYS
The invention relates to methods and kits for detecting a virus, e.g., a respiratory virus such as a coronavirus, in a biological sample. The invention also relates to methods and kits for detecting and/or quantifying biomarkers, e.g., antibody biomarkers against a viral antigen; inflammatory and/or tissue damage response biomarkers; and/or extracellular vesicles in response to a viral infection.
DETECTION ASSAYS FOR CORONAVIRUS NEUTRALIZING ANTIBODIES
The disclosure provides methods for determining the presence of coronavirus neutralizing antibodies in a sample as well as associated compositions and kits. The methods of the disclosure use recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike (S) glycoprotein or a fragment or a derivative thereof. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are used for determining the presence of SARS-CoV-2 neutralizing antibodies.
METHOD OF DETECTING VIRUS HAVING HEMAGGLUTININ-ESTERASE ACTIVITY
A method of detecting a virus having a hemagglutinin-esterase activity in a sample is disclosed, the method includes: contacting the sample with a substrate for an enzyme of hemagglutinin-esterase (HE) of coronavirus or hemagglutinin-esterase fusion protein (HEF) of influenza C virus; and detecting activity of the enzyme, the detection of the activity indicates that the sample contains coronavirus or influenza C virus.
PEPTIDE SEQUENCES FOR DETECTION AND DIFFERENTIATION OF ANTIBODY RESPONSES TO SARS-COV-2 AND OTHER HUMAN CORONA VIRUSES
The current disclosure provides compositions, methods, and kits for detecting the exposure to and infection by certain viruses. Specifically, the current disclosure allows for the rapid differential serological detection of exposure to, and infection by viruses. In particular, the current disclosure allows for the rapid differential serological detection of exposure to, and infection by corona virus (SARS-CoV-2). The current disclosure provides for peptides for the differential detection of SARS-CoV-2.